Affordable Access

deepdyve-link deepdyve-link
Publisher Website

Novel viral vectored vaccines for the prevention of influenza.

Authors
  • 1
  • 1 Jenner Institute, University of Oxford, Oxford, United Kingdom. [email protected] , (United Kingdom)
Type
Published Article
Journal
Molecular medicine (Cambridge, Mass.)
1528-3658
Publication Date
Volume
18
Pages
1153–1160
Identifiers
DOI: 10.2119/molmed.2012.00147
PMID: 22735755
Source
Medline
License
Unknown

Abstract

Influenza represents a substantial global healthcare burden, with annual epidemics resulting in 3-5 million cases of severe illness with a significant associated mortality. In addition, the risk of a virulent and lethal influenza pandemic has generated widespread and warranted concern. Currently licensed influenza vaccines are limited in their ability to induce efficacious and long-lasting herd immunity. In addition, and as evidenced by the H1N1 pandemic in 2009, there can be a significant delay between the emergence of a pandemic influenza and an effective, antibody-inducing vaccine. There is, therefore, a continued need for new, efficacious vaccines conferring cross-clade protection-obviating the need for biannual reformulation of seasonal influenza vaccines. Development of such a vaccine would yield enormous health benefits to society and also greatly reduce the associated global healthcare burden. There are a number of alternative influenza vaccine technologies being assessed both preclinically and clinically. In this review we discuss viral vectored vaccines, either recombinant live-attenuated or replication-deficient viruses, which are current lead candidates for inducing efficacious and long-lasting immunity toward influenza viruses. These alternate influenza vaccines offer real promise to deliver viable alternatives to currently deployed vaccines and more importantly may confer long-lasting and universal protection against influenza viral infection.

Statistics

Seen <100 times